PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.54%
Revenue growth at 50-75% of 3088.T's 3.97%. Martin Whitman would worry about competitiveness or product relevance.
2.13%
Gross profit growth under 50% of 3088.T's 6.07%. Michael Burry would be concerned about a severe competitive disadvantage.
-4.04%
Negative EBIT growth while 3088.T is at 33.49%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
8.13%
Operating income growth under 50% of 3088.T's 22.98%. Michael Burry would be concerned about deeper cost or sales issues.
-4.25%
Negative net income growth while 3088.T stands at 34.91%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.26%
Negative EPS growth while 3088.T is at 36.73%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-4.26%
Negative diluted EPS growth while 3088.T is at 36.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.82%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 34.19%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
-10.63%
Negative 5Y CAGR while 3088.T stands at 23.16%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
34.92%
3Y revenue/share CAGR above 1.5x 3088.T's 10.69%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
189.89%
Net income/share CAGR 1.25-1.5x 3088.T's 149.93%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
14.72%
Below 50% of 3088.T's 114.96%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
61.26%
3Y net income/share CAGR 1.25-1.5x 3088.T's 43.34%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
132.27%
10Y equity/share CAGR 1.25-1.5x 3088.T's 90.41%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
27.36%
Below 50% of 3088.T's 61.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.35%
3Y equity/share CAGR above 1.5x 3088.T's 22.52%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Firm’s AR is declining while 3088.T shows 21.03%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.34%
Inventory is declining while 3088.T stands at 3.67%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.61%
Negative asset growth while 3088.T invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.83%
BV/share growth above 1.5x 3088.T's 2.26%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.07%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
0.53%
SG&A declining or stable vs. 3088.T's 3.34%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.